In this new study, Shannon Stott, PhD & Brian Nahed, MD, MSc describe a new technique that uses microfluidics and engineered nanosurfaces to capture EVs released from glioblastoma multiforme.
Brian Nahed, MD, MSc
Brian Nahed, MD, MSc
Neurosurgical Oncology / Brain Tumor Surgeon / MGH Brain Tumor Center
Associate Professor, Harvard Medical School
Associate Director MGH Neurosurgery Program and Neurosurgical Spine
Departments, Centers, & Programs:
Pappas Center for Neuro Oncology
55 Fruit Street
Boston, MA 02114
- MSc, Harvard T. H Chan School of Public Health
- MD, Yale University School of Medicine
- Residency, Massachusetts General Hospital
- Fellowship, New England Baptist Hospital
American Board Certifications
- Neurological Surgery, American Board of Neurological Surgery
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Circulating Tumor Cells in Brain Tumor Patients and Blood Based Biomarkers for Brain Tumor Patients
Dr. Brian Nahed's research recently identified the first evidence of tumor cells in the blood of patients with brain tumors - a landmark finding which changes our understanding of brain tumors and the blood. Dr. Nahed and his colleagues developed the first device which they used to identify, capture, and analyze circulating tumor cells in the blood of patients with brain cancer. Through a collaboration between bioengineers, molecular biologists and clinicians, a circulating tumor cell capture device was developed to capture and detect tumor cells from patients with cancer. Under the mentorship of Drs. Daniel Haber, Shyamala Maheswaran, and Mehmet Toner, they aim to harness this technology to genetically characterize tumor cells without needing an invasive biopsy, and determine responsiveness to targeted cancer drugs. It also offers the opportunity to study cancer stem cells or metastatic precursors, thought to be at the origin of cancer spread via the bloodstream, to define their molecular vulnerabilities and help design new therapies to prevent cancer metastasis.
Dr. Nahed has joined Dr. Shannon Stott to develop the first clinical tool to identify and monitor brain tumor patients using a blood test - expanding on their individual work on circulating tumor cells and exosomes. They are actively enrolling patients into their NIH funded research program.
For more information, please click here.
Dr Nahed has 132 publications in peer-reviewed journals and has given hundreds of presentations, and continues to publish book chapters, scientific and patient centered blogs. Please refer to PubMed for a complete list of Dr Nahed's publications.
Leader in Liquid Biopsy Research and the first to develop a blood test for patients with brain tumors
Dr. Brian Nahed and Dr. Shannon Stott have developed the first blood based test to diagnose brain tumors from patient's blood. They have been awarded several grants, including an R01 from the NIH (National Institutes for Health) to develop a liquid biopsy for patients with brain tumors.
Congress of Neurological Surgeons
Dr. Nahed serves on the executive committee of the congress of neurological surgeons where he is focused on improving the education of neurosurgeons nationally and internationally. Dr. Nahed currently serves as the annual meeting chair, the co-chair of the CNS leadership institute, and the co-chair of the development committee.
- Nov | 18 | 2016
A Massachusetts General Hospital Neurosurgeon Works to Develop the First Blood-Based Test for Patients with Brain Tumors.
- Nov | 1 | 2018
In this new study, Shannon Stott, PhD and Brian Nahed, MD, MSc describe a new technique that uses microfluidics and engineered nanosurfaces to capture EVs released from glioblastoma multiforme.